Target Identification and Validation
The identification and validation of novel biological targets or mechanisms which underpin diseases within our Therapeutic Focus is a core component of the NGM Open Innovation strategy.
We will form collaborations with partner institutions which are based on a single target hypothesis or a portfolio of such ideas. Eisai can assist with project strategy, experimental design, tool compound provision or other such capabilities required to provide rigorous validation of novel target hypotheses.
Examples of a Target Identification and Validation alliances that have been established by NGM Open Innovation include the Alzheimer’s Research UK Dementia Consortium and the Eisai: University College London Collaboration.